In our subgroup analyses, we stratified the 4 cohorts into 4 groups according to ER and HER2, based on the prognostic17, 18, 19, 20, 21 and treatment grouping of breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.